EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY 4.0

Safety, efficacy, and pharmacokinetics of icatibant treatment in Japanese pediatric patients with hereditary angioedema: A phase 3, open‐label study

Michihiro Hide iD, Yi Wang, Nobuhito Dote, Kou Miyakawa, Kenkichi Sugiura, Kazuyuki Ishida iD

The Journal of Dermatology · 2023

DOI: 10.1111/1346-8138.16883 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift The Journal of Dermatology, 2023. Verfasst von Michihiro Hide und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hiroshima Citizens Hospital, Hiroshima, Japan. Hauptthemen laut MEDLINE: Angioedemas, Hereditary, Bradykinin B2 Receptor Antagonists. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company Limited, Japan, Takeda Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We evaluated the safety, efficacy, and pharmacokinetics of subcutaneous weight‐adjusted icatibant for the treatment of acute hereditary angioedema attacks in Japanese pediatric patients. Two patients (aged 10–13 and 6–9 years) received icatibant for a total of four attacks. Each attack was abdominal and/or cutaneous and was treated with a single icatibant injection. Mild or moderate injection‐site reactions were the only adverse events reported. Time to onset of symptom relief was 0.9–1.0 h. Icatibant was rapidly absorbed, with a pharmacokinetic profile consistent with previous studies. Simulated exposure levels were consistent with non‐Japanese pediatric patients. These results support the safety and efficacy of icatibant in Japanese pediatric patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angioedemas, HereditaryBradykinin B2 Receptor AntagonistsChildHumansBradykininEast Asian PeopleInjections, SubcutaneousTreatment OutcomeAdolescent

Stichwörter der Autor:innen

Japanhereditary angioedemaicatibantpediatricsphase 3 clinical trial

Substanzen

BradykininicatibantBradykinin B2 Receptor Antagonists

Autor:innen und Institutionen

  • Department of Dermatology, Hiroshima Citizens Hospital, Hiroshima, Japan.
  • Department of Dermatology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Quantitative Clinical Pharmacology, Takeda Development Center Americas Inc., Cambridge, Massachusetts, USA.
  • PRA Development Center KK, Osaka, Japan.
  • Takeda Development Center Japan, Takeda Pharmaceutical Company Limited, Osaka, Japan.

ORCID-Profile: Michihiro Hide, Kazuyuki Ishida

Förderung

  • Takeda Pharmaceutical Company Limited, Japan
  • Takeda Pharmaceutical Company

Zitieren

APA

Hide, M., Wang, Y., Dote, N., Miyakawa, K., Sugiura, K., & Ishida, K. (2023). Safety, efficacy, and pharmacokinetics of icatibant treatment in Japanese pediatric patients with hereditary angioedema: A phase 3, open‐label study. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.16883

Vancouver

Hide M, Wang Y, Dote N, Miyakawa K, Sugiura K, Ishida K. Safety, efficacy, and pharmacokinetics of icatibant treatment in Japanese pediatric patients with hereditary angioedema: A phase 3, open‐label study. The Journal of Dermatology. 2023. doi:10.1111/1346-8138.16883

BibTeX
@article{Hide2023,
  author = {Hide, Michihiro and Wang, Yi and Dote, Nobuhito and Miyakawa, Kou and Sugiura, Kenkichi and Ishida, Kazuyuki},
  title = {Safety, efficacy, and pharmacokinetics of icatibant treatment in Japanese pediatric patients with hereditary angioedema: A phase 3, open‐label study},
  journal = {The Journal of Dermatology},
  year = {2023},
  doi = {10.1111/1346-8138.16883}
}
Kostenlos starten →